Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Prevalence of Metabolic Dysfunction–Associated Fatty Liver Disease Among Patients With Diabetic Kidney Disease: A Systematic Review and Meta-Analysis Publisher



Rahmanian M1 ; Deravi N1 ; Poudineh M2 ; Poopak A3 ; Mirmohammadali SN4 ; Fekrvand S6 ; Tadbir K6 ; Ebrahimian S7 ; Zargarzadeh N6 ; Pirzadeh M7 ; Abdi A8 ; Firouzabadi FD9 ; Mechanick JI10
Authors
Show Affiliations
Authors Affiliations
  1. 1. Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Student Research Committee, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran
  3. 3. Endocrinology and Metabolism Research Center (EMRC), School of Medicine, Vali-Asr Hospital, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. College of Health & amp
  5. 5. Human Sciences, Kansas State University, Manhattan, 66502, KS, United States
  6. 6. School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. School of Midwifery, Babol University of Medical Sciences, Babol, Iran
  8. 8. Student Research Committee, School of Medicine, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran
  9. 9. Department of Radiology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, United States
  10. 10. The Marie-Josee and Henry R. Kravis Center for Cardiovascular Health at Mount Sinai Heart, and Division of Endocrinology, Diabetes and Bone Disease, Icahn School of Medicine at Mount Sinai, New York, NY, United States

Source: Egyptian Liver Journal Published:2024


Abstract

Background: Mechanistic relationships between metabolic dysfunction–associated fatty liver disease (MAFLD) and chronic kidney disease are well characterized. Specifically, in type 2 diabetes (T2D), insulin resistance leads to MAFLD, and hyperglycemia leads to microvascular complications such as diabetic kidney disease (DKD). This systematic review and meta-analysis aims to describe the specific association between MAFLD and DKD for the first time. Methods: PubMed, Web of Science, Google Scholar, and Scopus databases were searched up to February 2023 to identify relevant published articles. After screening the titles, abstracts, and full texts of the retrieved articles, cross-sectional studies and cohorts reporting on MAFLD in patients with DKD were identified and then analyzed. Results: A total of 2615 articles were identified, of which 5 had sufficient data and fulfilled the eligibility criteria for meta-analysis. A total of 2345 patients with DKD were in the included studies. The prevalence rates of radiologically diagnosed MAFLD among patients with DKD ranged from 25 to 96%. The pooled prevalence rate of radiologically diagnosed MAFLD among patients with DKD was 0.55 (95% CI = 0.21–0.89, I2 = 99.79%, P-value < 0.01). Conclusion: MAFLD is prevalent in patients with DKD. This finding emphasizes the need for aggressive case finding and then guideline-directed medical therapy of MAFLD, especially in patients with T2D and DKD to prevent further complications. Future studies should investigate mechanisms underpinning MAFLD and DKD in patients with T2D, especially in the context of cardiometabolic risk. © The Author(s) 2024.
Related Docs
1. Non-Alcoholic Fatty Liver Disease and Incidence of Microvascular Complications of Diabetes in Patients With Type 2 Diabetes: A Prospective Cohort Study, Frontiers in Endocrinology (2023)
2. Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the Covid-19 Pandemic: A Review of Current Literature, Advances in Therapy (2020)
3. Metabolically Healthy and Unhealthy Obesity and the Progression of Liver Fibrosis: A Cross-Sectional Study, Clinics and Research in Hepatology and Gastroenterology (2021)
4. An Overview of Fgf19 and Fgf21: The Therapeutic Role in the Treatment of the Metabolic Disorders and Obesity, Hormone and Metabolic Research (2018)
5. Association of Non-Alcoholic Fatty Liver Disease With Microvascular Complications of Type 2 Diabetes, Primary Care Diabetes (2019)
Experts (# of related papers)
View all Related Experts
Alireza Esteghamati (2)
Ahmad Esmaillzadeh (1)